Communications Medicine (Jan 2022)

Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth

  • Kevin M. Blum,
  • Jacob C. Zbinden,
  • Abhay B. Ramachandra,
  • Stephanie E. Lindsey,
  • Jason M. Szafron,
  • James W. Reinhardt,
  • Megan Heitkemper,
  • Cameron A. Best,
  • Gabriel J. M. Mirhaidari,
  • Yu-Chun Chang,
  • Anudari Ulziibayar,
  • John Kelly,
  • Kejal V. Shah,
  • Joseph D. Drews,
  • Jason Zakko,
  • Shinka Miyamoto,
  • Yuichi Matsuzaki,
  • Ryuma Iwaki,
  • Hira Ahmad,
  • Robbie Daulton,
  • Drew Musgrave,
  • Matthew G. Wiet,
  • Eric Heuer,
  • Emily Lawson,
  • Erica Schwarz,
  • Michael R. McDermott,
  • Rajesh Krishnamurthy,
  • Ramkumar Krishnamurthy,
  • Kan Hor,
  • Aimee K. Armstrong,
  • Brian A. Boe,
  • Darren P. Berman,
  • Aaron J. Trask,
  • Jay D. Humphrey,
  • Alison L. Marsden,
  • Toshiharu Shinoka,
  • Christopher K. Breuer

DOI
https://doi.org/10.1038/s43856-021-00063-7
Journal volume & issue
Vol. 2, no. 1
pp. 1 – 21

Abstract

Read online

Plain language summary Surgery to correct defects in the heart that are present at birth sometimes requires the use of artificial blood vessels called vascular grafts. Tissue-engineered vascular grafts (TEVGs) are scaffolds seeded with cells that can develop into functional blood vessels over time. We conducted a series of laboratory and computer-based experiments to investigate how TEVGs develop into functional blood vessels, and demonstrated two phases of changes to the TEVG after implantation: an early phase driven by inflammation, and a later phase driven by the mechanical properties of the tissue. At later time points, the resulting blood vessels demonstrated the ability to grow and respond to blood flow in similar ways to the body’s own blood vessels. These results provide insight into the processes by which TEVGs become functional blood vessels, with implications for future clinical use of this technology.